Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Objective: The aim of this review is addressing the mechanisms of asbestos carcinogenesis, including chronic inflammation and autophagy-mediated cell survival, and propose potential innovative therapeutic targets to prevent mesothelioma development or improve drug efficacy by reducing inflammation and autophagy. Background: Diffuse malignant pleural mesothelioma is an aggressive cancer predominantly related to chronic inflammation caused by asbestos exposure. Millions of individuals have been exposed to asbestos or to other carcinogenic mineral fibers occupationally or environmentally, resulting in an increased risk of developing mesothelioma. Overall patient survival rates are notably low (about 8–14 months from the time of diagnosis) and mesothelioma is resistant to existing therapies. Additionally, individuals carrying inactivating germline mutations in the BRCA-associated protein 1 (BAP1) gene and other genes are predisposed to developing cancers, prevalently mesothelioma. Their risk of developing mesothelioma further increases upon exposure to asbestos. Recent studies have revealed the mechanisms and the role of inflammation in asbestos carcinogenesis. Biomarkers for asbestos exposure and malignant mesothelioma have also been identified. These findings are leading to the development of novel therapeutic approaches to prevent or delay the growth of mesothelioma. Methods: Review of full length manuscripts published in English from January 1980 to February 2021 gathered from PubMed.gov from the National Center of Biotechnology Information and the National Library of Medicine were used to inform this review. Conclusions: Key regulators of chronic inflammation mediate asbestos-driven mesothelial cell transformation and survival through autophagic pathways. Recent studies have elucidated some of the key mechanisms involved in asbestos-induced chronic inflammation, which are largely driven by extracellular high mobility group box 1 (HMGB1). Upon asbestos exposure, mesothelial cells release HMGB1 from the nucleus to the cytoplasm and extracellular space, where HMGB1 initiates an inflammatory response. HMGB1 translocation and release also activates autophagy and other pro-survival mechanisms, which promotes mesothelioma development. HMGB1 is currently being investigated as a biomarker to detect asbestos exposure and to detect mesothelioma development in its early stage when therapy is more effective. In parallel, several approaches inhibiting HMGB1 activities have been studied and have shown promising results. Moreover, additional cytokines, such as IL-1β and TNF-α are being targeted to interfere with the inflammatory process that drives mesothelioma growth. Developing early detection methods and novel therapeutic strategies is crucial to prolong overall survival of patients with mesothelioma. Novel therapies targeting regulators of asbestos-induced inflammation to reduce mesothelioma growth may lead to clinical advancements to benefit patients with mesothelioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In turn, HMGB1 and pro-inflammatory cytokines promote the recruitment of macrophages and, together with ROS, sustain the chronic inflammatory process and DNA damage leading to mesothelial cell transformation over the years [1,21].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“EMT is an essential pathogenic process in tumor progression allowing epithelial cells to acquire characteristics of mesenchymal cells (26).”
BackgroundYang, Y., Li, S., Yang, Q., Shi, Y., Zheng, M., Liu, Y., Chen, F., Song, G., Xu, H., Wan, T., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358696 · Cited by 3,253
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes
Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., et al. (1992) · Nature · doi:10.1038/356768a0 · Cited by 2,572 · cited 1×
“The activated NLRP3 inflammasome controls and promotes the secretion of IL-1β and IL-18 by caspase-1 cleaving pro-IL-1β and pro-IL-18 to their mature forms (50,51).”
BackgroundTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Molecular mechanisms regulating NLRP3 inflammasome activation
Jo, E.-K., Kim, J. K., Shin, D.-M., & Sasakawa, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.95 · Cited by 1,378
The role for autophagy in cancer
White, E. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73941 · Cited by 1,332
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434651100 · Cited by 1,126
Self-citationGermline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076 · cited 1×
“During the past decade, numerous studies have confirmed and expanded upon our discovery that mesothelioma is frequent in families carrying germline mutations of BAP1 and other tumor suppressor genes (59,60).”
BackgroundSelf-citationInflammasome activation and regulation: toward a better understanding of complex mechanisms
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Discovery · doi:10.1038/s41421-020-0167-x · Cited by 1,026
BAP1 links metabolic regulation of ferroptosis to tumour suppression
Zhang, Y., Shi, J., Liu, X., Feng, L., Gong, Z., Koppula, P., Sirohi, K., Li, X., Wei, Y., Lee, H., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0178-0 · Cited by 1,013 · cited 2×
“Furthermore, the tumor suppressor activity of BAP1 has been recently linked to promoting ferroptosis by modulating the repression of cystine/glutamate antiporter SLC7A11 expression (3,23,24).”
BackgroundRothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Martinon, F., & Tschopp, J. (2004) · Cell · doi:10.1016/j.cell.2004.05.004 · Cited by 938
Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release
Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D. J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120189 · Cited by 720
Self-citationSchiraldi, M., Raucci, A., Muñoz, L. M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111739 · Cited by 676
Iron-induced carcinogenesis: The role of redox regulation
Toyokuni, S. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)02111-6 · Cited by 471 · cited 1×
“Elevated levels of iron favor excessive ROS production and DNA damage catalyzed by oxidation: common hallmarks of cancer (20).”
BackgroundInterleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444 · cited 1×
“IL-1β secretion is essential to inflammation-induced mesothelioma because IL-1β regulates other cytokines contributing to mesothelioma development (52,53).”
BackgroundBAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
Bononi, A., Giorgi, C., Patergnani, S., Larson, D., Verbruggen, K., Tanji, M., Pellegrini, L., Signorato, V., Olivetto, F., Pastorino, S., et al. (2017) · Nature · doi:10.1038/nature22798 · Cited by 401
Self-citationHMGB1 Develops Enhanced Proinflammatory Activity by Binding to Cytokines
Sha, Y., Zmijewski, J., Xu, Z., & Abraham, E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2531 · Cited by 393 · cited 1×
“Once HMGB1 is released into the extracellular space, it binds directly with IL-1β and increases the production of TNF-α and macrophage inflammatory protein 2 (MIP-2 or CXCL2), which have pro-inflammatory activity (41).”
BackgroundMalignant mesothelioma: Facts, Myths, and Hypotheses
Carbone, M., Ly, B. H., Dodson, R. F., Pagano, I., Morris, P. T., Dogan, U. A., Gazdar, A. F., Pass, H. I., & Yang, H. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22724 · Cited by 376 · cited 1×
“Malignant pleural mesothelioma, a rare and aggressive malignancy due to mesothelial cell transformation, is the most common cancer caused by prolonged asbestos exposure (1,2).”
BackgroundSelf-citationRole of inflammatory response in liver diseases: Therapeutic strategies
Campo, J. A. D., Gallego, P., & Grande, L. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i1.1 · Cited by 348
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335 · cited 6×
“At the time of diagnosis, diffuse pleural mesothelioma, which must be distinguished from the exceedingly rare, localized forms, is very often at advanced stages and median survival rates are approximately 8–14 months (3).”
BackgroundInfluentialSelf-citationAn overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Musumeci, D., Roviello, G. N., & Montesarchio, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.001 · Cited by 334 · cited 1×
“Since the HMGB1 release appears necessary for mesothelioma progression, targeting HMGB1 has been explored as a potential therapy for mesothelioma (19,39,93,94).”
BackgroundHigh Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Nasu, M., Emi, M., Pastorino, S., Tanji, M., Powers, A., Luk, H., Baumann, F., Zhang, Y.-A., Gazdar, A., Kanodia, S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000471 · Cited by 326 · cited 1×
“The critical role of BAP1 in mesothelioma is supported by the frequent somatic biallelic inactivation of this gene in sporadic mesothelioma, which account for more than 60% of mesotheliomas (65,66), a malignancy in which recurrent genetic mutations are rare (67–69).”
BackgroundSelf-citationYang, H., Bocchetta, M., Kroczynska, B., Elmishad, A. G., Chen, Y., Liu, Z., Bubici, C., Mossman, B. T., Pass, H. I., Testa, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604008103 · Cited by 322
Self-citationGuo, G., Chmielecki, J., Goparaju, C., Heguy, A., Dolgalev, I., Carbone, M., Seepo, S., Meyerson, M., & Pass, H. I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1008 · Cited by 321 · cited 1×
“Moreover, Anakinra treatment increased Nf2+/− and Cdkna2+/− mice survival exposed to asbestos (38,68), suggesting that Anakinra may mitigate mesothelioma progression by reducing inflammation.”
BackgroundSelf-citationBiological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287 · cited 1×
“We have recently reviewed the role of genetics in causing mesothelioma (3), the BAP1 cancer syndrome (75), and the role and mechanisms of Gene X Environment interaction in human cancer including mesothelioma (62) in detail, and therefore we will not further discuss these issues here.”
BackgroundSelf-citationYang, H., Rivera, Z., Jube, S., Nasu, M., Bertino, P., Goparaju, C., Franzoso, G., Lotze, M. T., Krausz, T., Pass, H. I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006542107 · Cited by 281 · cited 5×
“Early studies in asbestos-driven carcinogenesis suggest that HMGB1 is released from the nucleus to the cytoplasm and to the extracellular space where HMGB1 induces an inflammatory response (4,12).”
BackgroundInfluentialSelf-citationJia, C., Zhang, J., Chen, H., Zhuge, Y., Chen, H., Qian, F., Zhou, K., Niu, C., Wang, F., Qiu, H., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2021-3 · Cited by 275
Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis
Yang, H., Testa, J. R., & Carbone, M. (2008) · Current Treatment Options in Oncology · doi:10.1007/s11864-008-0067-z · Cited by 274 · cited 1×
“Compared to other cell types, HM are more vulnerable to asbestos cytotoxicity (13,14).”
BackgroundSelf-citationCancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma
Jube, S., Rivera, Z. S., Bianchi, M. E., Powers, A., Wang, E., Pagano, I., Pass, H. I., Gaudino, G., Carbone, M., & Yang, H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3481 · Cited by 255 · cited 10×
“Similar to aspirin and BoxA, anti-HMGB1 and anti-RAGE antibodies reduced anchorage-independent cell growth in vitro (39).”
BackgroundResultInfluentialSelf-citationMesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Baumann, F., Flores, E., Napolitano, A., Kanodia, S., Taioli, E., Pass, H., Yang, H., & Carbone, M. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu227 · Cited by 254
Self-citationBocchetta, M., Di Resta, I., Powers, A., Fresco, R., Tosolini, A., Testa, J. R., Pass, H. I., Rizzo, P., & Carbone, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170207097 · Cited by 243 · cited 1×
“Compared to other cell types, HM are more vulnerable to asbestos cytotoxicity (13,14).”
BackgroundSelf-citationMolecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma
Carbone, M., & Yang, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2259 · Cited by 229
Self-citationFrequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Panou, V., Gadiraju, M., Wolin, A., Weipert, C. M., Skarda, E., Husain, A. N., Patel, J. D., Rose, B., Zhang, S. R., Weatherly, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5204 · Cited by 229
Heintz, N. H., Janssen-Heininger, Y. M. W., & Mossman, B. T. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0206tr · Cited by 182 · cited 1×
“It was demonstrated that upregulation of the AP-1 component Fra-1 in response to asbestos modulates malignant transformation of mesothelial cells (31,32).”
BackgroundRole of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases
Huang, S. X. L., Jaurand, M.-C., Kamp, D. W., Whysner, J., & Hei, T. K. (2011) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2011.556051 · Cited by 163 · cited 2×
“The accumulation of survived mesothelial cells carrying DNA defects induced by asbestos and asbestos-generated ROS and RNS eventually leads to mesothelioma development.”
BackgroundNapolitano, A., Pellegrini, L., Dey, A., Larson, D., Tanji, M., Flores, E. G., Kendrick, B., Lapid, D., Powers, A., Kanodia, S., et al. (2016) · Oncogene · doi:10.1038/onc.2015.243 · Cited by 161 · cited 1×
“, Gene X Environment interaction (38,63), and BAP1 germline mutations interact with other tumor suppressor gene mutations to favor mesothelioma development, i.”
BackgroundSelf-citationBroaddus, V. C., Yang, L., Scavo, L. M., Ernst, J. D., & Boylan, A. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119010 · Cited by 161 · cited 1×
“Additionally, HM susceptibility to asbestos cytotoxicity was initially proposed to be associated predominantly with apoptosis (10).”
BackgroundAsbestos is not just asbestos: an unrecognised health hazard
Baumann, F., Ambrosi, J.-P., & Carbone, M. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70257-2 · Cited by 158 · cited 1×
“Chrysotile was mined in the United States until 2002 (7).”
BackgroundSelf-citationHassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gulsuner, S., Gadiraju, M., Panou, V., Gao, S., Mian, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821510116 · Cited by 158
From inflammation to gastric cancer: Role of Helicobacter pylori
Zhang, X., Zhang, P.-Y., & Aboul‐Soud, M. A. M. (2016) · Oncology Letters · doi:10.3892/ol.2016.5506 · Cited by 156
Liu, J., Brass, D. M., Hoyle, G. W., & Brody, A. R. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65698-2 · Cited by 153 · cited 1×
“Knocking out TNF-α receptors was sufficient to protect against asbestos-induced fibroproliferative lesions (40), which underscores the importance of TNF-α signaling in asbestos-induced inflammation.”
BackgroundAsbestos-Derived Reactive Oxygen Species Activate TGF-Β1
Pociask, D. A., Sime, P. J., & Brody, A. R. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700109 · Cited by 149
Tumour predisposition and cancer syndromes as models to study gene–environment interactions
Carbone, M., Arron, S. T., Beutler, B., Bononi, A., Cavenee, W., Cleaver, J. E., Croce, C. M., D’Andrea, A., Foulkes, W. D., Gaudino, G., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0265-y · Cited by 147 · cited 2×
“About 30% of carriers of germline BAP1 mutations have developed diffuse malignant mesothelioma (62).”
BackgroundSelf-citationPastorino, S., Yoshikawa, Y., Pass, H. I., Emi, M., Nasu, M., Pagano, I., Takinishi, Y., Yamamoto, R., Minaai, M., Hashimoto-Tamaoki, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0352 · Cited by 143
Self-citationTreatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice
Sitia, G., Iannacone, M., Müller, S., Bianchi, M. E., & Guidotti, L. G. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306173 · Cited by 134 · cited 1×
“Moreover, asbestos-induced autophagy was completely inhibited by treating HM with BoxA (5), an HMGB1 antagonist (5,39,80,81).”
BackgroundGermline BAP1 mutations induce a Warburg effect
Bononi, A., Yang, H., Giorgi, C., Patergnani, S., Pellegrini, L., Su, M., Xie, G., Signorato, V., Pastorino, S., Morris, P., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.95 · Cited by 133
Self-citationRamos‐Niño, M. E., Timblin, C. R., & Mossman, B. T. (2002) · PubMed · Cited by 125
Hillegass, J. M., Miller, J. M., MacPherson, M. B., Westbom, C. M., Sayan, M., Thompson, J. K., Macura, S. L., Perkins, T. N., Beuschel, S. L., Alexeeva, V., et al. (2013) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-10-39 · Cited by 120 · cited 2×
“Activation of the NLRP3 inflammasome in macrophages and HM after asbestos exposure initiates the downstream inflammatory response by secretion of pro-inflammatory cytokines (43).”
BackgroundSelf-citationTsao, A. S., Lindwasser, O. W., Adjei, A. A., Adusumilli, P. S., Beyers, M. L., Blumenthal, G. M., Bueno, R., Burt, B. M., Carbone, M., Dahlberg, S. E., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2036 · Cited by 120
Self-citationScientific Advances and New Frontiers in Mesothelioma Therapeutics
Mutti, L., Peikert, T., Robinson, B. W. S., Scherpereel, A., Tsao, A. S., de Perrot, M., Woodard, G. A., Jablons, D. M., Wiens, J., Hirsch, F. R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.011 · Cited by 112
Self-citationLiu, W., Ernst, J. D., & Courtney Broaddus, V. (2000) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.23.3.4094 · Cited by 111 · cited 1×
“In efforts to remove inhaled asbestos fibers, macrophages and mesothelial cells attempt to envelop and phagocytize these fibers, which causes a wide range of cytotoxic effects including intracellular oxidation, DNA damage, cell cycle delay, cell death, and release of superoxide and cytokines (15,16).”
BackgroundQi, F., Okimoto, G., Jube, S., Napolitano, A., Pass, H. I., Laczko, R., DeMay, R. M., Khan, G., Tiirikainen, M., Rinaudo, C., et al. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.07.029 · Cited by 110 · cited 16×
“Qi F, Okimoto G, Jube S, et al. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling.”
BackgroundInfluentialSelf-citationWhite, R. R., Milholland, B., de Bruin, A., Curran, S., Laberge, R.-M., van Steeg, H., Campisi, J., Maslov, A. Y., & Vijg, J. (2015) · Nature Communications · doi:10.1038/ncomms7790 · Cited by 107 · cited 1×
“It was also shown previously that asbestos exposure causes DNA damage, such as double-strand breaks (76,77), which are associated with the loss of nuclear HMGB1 (78).”
BackgroundHow Asbestos and Other Fibers Cause Mesothelioma
Gaudino, G., Xue, J., & Yang, H. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.02.01 · Cited by 102 · cited 1×
“Malignant pleural mesothelioma, a rare and aggressive malignancy due to mesothelial cell transformation, is the most common cancer caused by prolonged asbestos exposure (1,2).”
BackgroundSelf-citationHMGB1 Increases IL-1β Production in Vascular Smooth Muscle Cells via NLRP3 Inflammasome
Kim, E. J., Park, S. Y., Baek, S. E., Jang, M. A., Lee, W. S., Bae, S. S., Kim, K., & Kim, C. D. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00313 · Cited by 101
A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results
Pass, H. I., Brewer, G. J., Dick, R., Carbone, M., & Merajver, S. D. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2008.03.016 · Cited by 97
Self-citationToyokuni, S. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.401 · Cited by 96 · cited 6×
“Elevated levels of iron favor excessive ROS production and DNA damage catalyzed by oxidation: common hallmarks of cancer (20).”
BackgroundInfluentialCSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Rivera, Z. S., Ferrone, S., Wang, X., Jube, S., Yang, H., Pass, H. I., Kanodia, S., Gaudino, G., & Carbone, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0628 · Cited by 94
Self-citationEvaluation of clonal origin of malignant mesothelioma
Comertpay, S., Pastorino, S., Tanji, M., Mezzapelle, R., Strianese, O., Napolitano, A., Baumann, F., Weigel, T., Friedberg, J., Sugarbaker, P., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0301-3 · Cited by 94 · cited 1×
“It was also found that because of the “field effect” of asbestos exposure and/or germline mutations, multiple foci of transformed cells may develop simultaneously: accordingly, mesothelioma is often a polyclonal malignancy (33).”
BackgroundSelf-citationArnold, K., Xu, Y., Sparkenbaugh, E., Li, M., Han, X., Zhang, X., Xia, K., Piegore, M., Zhang, F., Zhang, X., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8075 · Cited by 94 · cited 1×
“pro-inflammatory activity of the HMGB1-RAGE axis and protect against acetaminophen/ paracetamol-induced acute liver failure in a mouse model (99), which makes 18-mer-HP a potential candidate to target HMGB1 release induced by asbestos exposure that is worth investigating in future studies.”
BackgroundAsbestos induces mesothelial cell transformation via HMGB1-driven autophagy
Xue, J., Patergnani, S., Giorgi, C., Suarez, J. S., Goto, K., Bononi, A., Tanji, M., Novelli, F., Pastorino, S., Xu, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007622117 · Cited by 90 · cited 17×
“Similar to aspirin and BoxA, anti-HMGB1 and anti-RAGE antibodies reduced anchorage-independent cell growth in vitro (39).”
BackgroundInfluentialSelf-citationKadariya, Y., Menges, C. W., Talarchek, J., Cai, K. Q., Klein-Szanto, A. J., Pietrofesa, R. A., Christofidou-Solomidou, M., Cheung, M., Mossman, B. T., Shukla, A., et al. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0347 · Cited by 89 · cited 4×
“Since IL-1β levels regulate the secretion of other pro-inflammatory cytokines, IL-1 receptor antagonists have been proposed as a therapeutic strategy to reduce inflammation in mesothelioma (38,54,55).”
BackgroundInfluentialAsbestos Surface Provides a Niche for Oxidative Modification
Nagai, H., Ishihara, T., Lee, W., Ohara, H., Okazaki, Y., Okawa, K., & Toyokuni, S. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02087.x · Cited by 86 · cited 2×
“Crocidolite and amosite fibers have high biopersistence and contain high amounts of iron that form iron-rich chemical structures (ferruginous bodies), and some other asbestos fibers harbor iron as a surface impurity (11).”
BackgroundAspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression
Yang, H., Pellegrini, L., Napolitano, A., Giorgi, C., Jube, S., Preti, A., Jennings, C. J., De Marchis, F., Flores, E. G., Larson, D., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.153 · Cited by 81
Self-citationGao, Y., Liang, M., Li, M., Fang, X., Liu, J., Lai, Y., Chen, J., Yao, W., Feng, X., Hu, L., et al. (2018) · Inflammation Research · doi:10.1007/s00011-018-1145-8 · Cited by 81
Bennett‐Guerrero, E., Swaminathan, M., Grigore, A. M., Roach, G. W., Aberle, L. G., Johnston, J. M., & Fink, M. P. (2008) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2008.08.005 · Cited by 80 · cited 1×
“EP has been included in some food products and used as therapeutics in various diseases other than cancer; thus, its use is considered to be safe for human health (97,98).”
BackgroundCharacteristics and modifying factors of asbestos‐induced oxidative DNA damage
Jiang, L., Nagai, H., Ohara, H., Hara, S., Tachibana, M., Hirano, S., Shinohara, Y., Kohyama, N., Akatsuka, S., & Toyokuni, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00934.x · Cited by 78 · cited 1×
“In efforts to remove inhaled asbestos fibers, macrophages and mesothelial cells attempt to envelop and phagocytize these fibers, which causes a wide range of cytotoxic effects including intracellular oxidation, DNA damage, cell cycle delay, cell death, and release of superoxide and cytokines (15,16).”
BackgroundSerum HMGB1 as a prognostic marker for malignant pleural mesothelioma
Tabata, C., Shibata, E., Tabata, R., Kanemura, S., Mikami, K., Nogi, Y., Masachika, E., Nishizaki, T., & Nakano, T. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-205 · Cited by 76 · cited 1×
“Accordingly, asbestos-exposed individuals have elevated HMGB1 serum levels and its levels further increased during mesothelioma development, suggesting that HMGB1 can be a potential biomarker for asbestos exposure and early detection of mesothelioma (4,39,57,58).”
BackgroundGenomic events associated with progression of pleural malignant mesothelioma
Ivanov, S. V., Miller, J., Lucito, R., Tang, C., Ivanova, A. V., Pei, J., Carbone, M., Cruz, C., Beck, A., Webb, C., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.23949 · Cited by 76
Self-citationProgress in the Management of Malignant Pleural Mesothelioma in 2017
McCambridge, A. J., Napolitano, A., Mansfield, A. S., Fennell, D. A., Sekido, Y., Nowak, A. K., Reungwetwattana, T., Mao, W., Pass, H. I., Carbone, M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.021 · Cited by 75
Self-citationNLRP3 promotes inflammation‐induced skin cancer but is dispensable for asbestos‐induced mesothelioma
Chow, M. T., Tschopp, J., Möller, A., & Smyth, M. J. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2012.46 · Cited by 74 · cited 1×
“However, there was no significant difference regarding the incidence of mesothelioma between the two groups (56), which suggested that asbestos-induced inflammation is initially inflammasome-dependent, but NLRP3 may not be essential during the later stage of chronic inflammation that causes mesothelioma development fo…”
BackgroundEthyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries
Yang, R., Zhu, S., & Tønnessen, T. I. (2016) · Journal of Inflammation · doi:10.1186/s12950-016-0144-1 · Cited by 69 · cited 1×
“Ethyl pyruvate (EP), a derivative of pyruvic acid, has shown effective to reduce inflammation (95,96).”
BackgroundHGF Mediates Cell Proliferation of Human Mesothelioma Cells through a PI3K/MEK5/Fra-1 Pathway
Ramos-Nino, M. E., Blumen, S. R., Sabo-Attwood, T., Pass, H., Carbone, M., Testa, J. R., Altomare, D. A., & Mossman, B. T. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0206oc · Cited by 68 · cited 1×
“Moreover, asbestos induces ROS production that activates TGF-β secretion (27) and the activation of activator-protein-1 (AP-1) (28,29), an important regulator of inflammation, cell proliferation, and transformation, ultimately influencing asbestos cytotoxicity (30,31).”
BackgroundSelf-citationPass, H. I., Mew, D., Carbone, M., Matthews, W. A., Donington, J. S., Baserga, R., Walker, C. L., Resnicoff, M., & Steinberg, S. M. (1996) · PubMed · Cited by 66
Self-citationEthyl pyruvate: A novel anti-inflammatory agent
Fink, M. P. (2003) · Critical Care Medicine · doi:10.1097/00003246-200301001-00008 · Cited by 64 · cited 1×
“Ethyl pyruvate (EP), a derivative of pyruvic acid, has shown effective to reduce inflammation (95,96).”
BackgroundBAP1 regulates different mechanisms of cell death
Affar, E. B., & Carbone, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1206-5 · Cited by 62 · cited 2×
“Furthermore, the tumor suppressor activity of BAP1 has been recently linked to promoting ferroptosis by modulating the repression of cystine/glutamate antiporter SLC7A11 expression (3,23,24).”
BackgroundSelf-citationHMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma
Pellegrini, L., Xue, J., LARSON, D. L., Pastorino, S., Jube, S., Forest, K. H., Saad-Jube, Z., Napolitano, A., Pagano, I., Negi, V. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15152 · Cited by 61 · cited 4×
“Since the HMGB1 release appears necessary for mesothelioma progression, targeting HMGB1 has been explored as a potential therapy for mesothelioma (19,39,93,94).”
BackgroundInfluentialSelf-citationImmunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
Onconase mediated NFKβ downregulation in malignant pleural mesothelioma
Goparaju, C. M., Blasberg, J. D., Volinia, S., Palatini, J., Ivanov, S., Donington, J. S., Croce, C., Carbone, M., Yang, H., & Pass, H. I. (2011) · Oncogene · doi:10.1038/onc.2010.643 · Cited by 56
Self-citationInflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma
Westbom, C., Thompson, J. K., Leggett, A., MacPherson, M., Beuschel, S., Pass, H., Vacek, P., & Shukla, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0145404 · Cited by 56 · cited 1×
“Since IL-1β levels regulate the secretion of other pro-inflammatory cytokines, IL-1 receptor antagonists have been proposed as a therapeutic strategy to reduce inflammation in mesothelioma (38,54,55).”
BackgroundSelf-citationSchwarznau, A., Hanson, M. S., Sperger, J. M., Schram, B. R., Danobeitia, J. S., Greenwood, K. K., Vijayan, A., & Fernandez, L. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21770 · Cited by 55
Rubartelli, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00099 · Cited by 55
Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases
Ying, S., Jiang, Z., He, X., Yu, M., Chen, R., Chen, J., Ru, G., Chen, Y., Chen, W., Zhu, L., et al. (2017) · Disease Markers · doi:10.1155/2017/5756102 · Cited by 54 · cited 1×
“Accordingly, asbestos-exposed individuals have elevated HMGB1 serum levels and its levels further increased during mesothelioma development, suggesting that HMGB1 can be a potential biomarker for asbestos exposure and early detection of mesothelioma (4,39,57,58).”
BackgroundHeterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma
Bononi, A., Goto, K., Ak, G., Yoshikawa, Y., Emi, M., Pastorino, S., Carparelli, L., Ferro, A., Nasu, M., Kim, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019652117 · Cited by 54 · cited 1×
“During the past decade, numerous studies have confirmed and expanded upon our discovery that mesothelioma is frequent in families carrying germline mutations of BAP1 and other tumor suppressor genes (59,60).”
BackgroundSelf-citationInhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
Echeverry, N., Ziltener, G., Barbone, D., Weder, W., Stahel, R. A., Broaddus, V. C., & Felley‐Bosco, E. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.124 · Cited by 51 · cited 1×
“Therefore, inhibiting autophagy has been proposed as a possible therapeutic approach to promote drug sensitivity and reduce tumor growth (5,6).”
BackgroundAsbestos induces activator protein-1 transactivation in transgenic mice.
Ding, M., Dong, Z., Chen, F., Pack, D., Ma, W. Y., Ye, J., Shi, X., Castranova, V., & Vallyathan, V. (1999) · PubMed · Cited by 51
Olofsson, K., & Mark, J. (1989) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(89)90105-2 · Cited by 50 · cited 1×
“Early studies suggested asbestos fibers mechanically interfere with chromosomal segregation during mitosis and cause DNA damage in HM, which eventually becomes mesothelioma (9).”
BackgroundCombined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice
Badhai, J., Pandey, G. K., Song, J.-Y., Krijgsman, O., Bhaskaran, R., Chandrasekaran, G., Kwon, M.-C., Bombardelli, L., Monkhorst, K., Grasso, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191257 · Cited by 49
BAP1: role in carcinogenesis and clinical implications
Kobrinski, D. A., Yang, H., & Kittaneh, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.24 · Cited by 48 · cited 1×
“The critical role of BAP1 in mesothelioma is supported by the frequent somatic biallelic inactivation of this gene in sporadic mesothelioma, which account for more than 60% of mesotheliomas (65,66), a malignancy in which recurrent genetic mutations are rare (67–69).”
BackgroundSelf-citationIto, F., Yanatori, I., Maeda, Y., Nimura, K., Ito, S., Hirayama, T., Nagasawa, H., Kohyama, N., Okazaki, Y., Akatsuka, S., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101616 · Cited by 45 · cited 2×
“Recent data show that asbestos fibers induce distinctive necrotic cell death, and the cells initially undergo lysosome-dependent cell death (LDCD) and then undergo ferroptosis (22).”
BackgroundThompson, J. K., Westbom, C. M., MacPherson, M. B., Mossman, B. T., Heintz, N. H., Spiess, P., & Shukla, A. (2014) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-11-24 · Cited by 44 · cited 1×
“Asbestos exposure causes oxidation of the antioxidant thioredoxin-1 (Trx1) and thioredoxin interacting protein (TXNIP) release: both contribute to the activation of the NLRP3 inflammasome (42,44).”
BackgroundTurini, S., Bergandi, L., Gazzano, E., Prato, M., & Aldieri, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010150 · Cited by 44 · cited 19×
“Qi F, Okimoto G, Jube S, et al. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling.”
BackgroundInfluentialMezzapelle, R., Rrapaj, E., Gatti, E., Ceriotti, C., Marchis, F. D., Preti, A., Spinelli, A. E., Perani, L., Venturini, M., Valtorta, S., et al. (2016) · Scientific Reports · doi:10.1038/srep22850 · Cited by 43
Huang, S. X. L., Partridge, M. A., Ghandhi, S. A., Davidson, M. M., Amundson, S. A., & Hei, T. K. (2012) · Environmental Health Perspectives · doi:10.1289/ehp.1104287 · Cited by 42 · cited 2×
“The accumulation of survived mesothelial cells carrying DNA defects induced by asbestos and asbestos-generated ROS and RNS eventually leads to mesothelioma development.”
Nasu, M., Carbone, M., Gaudino, G., Ly, B. H., Bertino, P., Shimizu, D. M., Morris, P., Pass, H. I., & Yang, H. (2011) · Genes & Cancer · doi:10.1177/1947601911412375 · Cited by 31
Self-citationGriffith, D. E., Miller, E. J., Gray, L. D., Idell, S., & Johnson, A. R. (1994) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.10.3.8117443 · Cited by 29 · cited 1×
“IL-1β secretion is essential to inflammation-induced mesothelioma because IL-1β regulates other cytokines contributing to mesothelioma development (52,53).”
BackgroundMatsushita, A., Sato, T., Mukai, S., Fujishita, T., Mishiro‐Sato, E., Okuda, M., Aoki, M., Hasegawa, Y., & Sekido, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0417-7 · Cited by 29 · cited 1×
“Since IL-1β levels regulate the secretion of other pro-inflammatory cytokines, IL-1 receptor antagonists have been proposed as a therapeutic strategy to reduce inflammation in mesothelioma (38,54,55).”
BackgroundBoth, K., Henderson, D. W., & Turner, D. R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590417 · Cited by 27 · cited 1×
“It was also shown previously that asbestos exposure causes DNA damage, such as double-strand breaks (76,77), which are associated with the loss of nuclear HMGB1 (78).”
BackgroundAndersen, P. H., & Jensen, N. J. (1984) · Food Additives & Contaminants · doi:10.1080/02652038409385855 · Cited by 24 · cited 1×
“EP has been included in some food products and used as therapeutics in various diseases other than cancer; thus, its use is considered to be safe for human health (97,98).”
BackgroundPietruska, J. R., Johnston, T., Zhitkovich, A., & Kane, A. B. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.1002312 · Cited by 22 · cited 1×
“It was also shown previously that asbestos exposure causes DNA damage, such as double-strand breaks (76,77), which are associated with the loss of nuclear HMGB1 (78).”
BackgroundDisselhorst, M., & Baas, P. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.16 · Cited by 16
MOLECULAR ACTIVATION OF ACTIVATOR PROTEIN-1 IN SILICA AND ASBESTOS-INDUCED CARCINOGENESIS
Vallyathan, V., Ding, M., Shi, X., & Castranova, V. (2000) · Inhalation Toxicology · doi:10.1080/08958378.2000.11463245 · Cited by 7 · cited 3×
“Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression.”
Background
Research works printed but not linked: 1
- [80]Jube SL, Rivera Z, Casalgrandi M, BoxA and ethyl pyruvate offer novel therapeutic approaches for human malignant mesothelioma. Cancer Res 2013; 73: 5557.
Cited by
Pyroptosis in inflammatory diseases and cancer
Rao, Z., Zhu, Y., Yang, P., Chen, Z., Xia, Y., Qiao, C., Liu, W., Deng, H., Li, J., Ning, P., et al. (2022) · Theranostics · doi:10.7150/thno.71086 · Cited by 800
“Chronic inflammation and pyroptosis also involves the development of asbestos-associated mesothelioma [105].”
BackgroundMangiante, L., Alcala, N., Sexton‐Oates, A., Genova, A. D., González-Pérez, A., Khandekar, A., Bergstrom, E. N., Kim, J., Liu, X., Blázquez‐Encinas, R., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01321-1 · Cited by 106
Nthunya, L. N., Mosai, A. K., López‐Maldonado, E. A., Bopape, M. F., Dhibar, S., Nuapia, Y. B., Ajiboye, T. O., Buledi, J. A., Solangi, A. R., Sherazi, S. T. H., et al. (2025) · Chemosphere · doi:10.1016/j.chemosphere.2025.144470 · Cited by 60
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Fennell, D. A., Sekido, Y., Baas, P., Husain, A. N., Fontecedro, A. C., Lim, E. K. S., Opitz, I., Simone, C. B., Brims, F., & Wong, M. C. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00640-3 · Cited by 47
“Asbestos fibres travelling to and deposited in the visceral pleura pro mote chronic inflammation 68 , which can induce mesothelioma 32 .”
Metadata
- Authors
- Zolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H.
- Affiliations
- University of Hawaiʻi at Mānoa (US)
- University of Hawaii Cancer Center (US)
- NYU Langone Health (US)
- Corresponding author
- Yang, Haining
- Venue
- Precision Cancer Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-09
- Volume
- 4
- Pages
- 27-27
- ISSN
- 2617-2216 (ISSN-L)
- PMC
- PMC8797751
- OpenAlex
- W3191102673
- Cited by
- 41
- References
- 107
- Citations by year
- 2026: 4 · 2025: 16 · 2024: 7 · 2023: 9 · 2022: 5
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Precision Cancer Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (5r01ca237235-05)
- National Cancer Institute (R01CA160715, U01CA214195, R01 CA237235)
- National Institute of Environmental Health Sciences (R01ES030948)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Social Sciences › Health › Occupational Health and Global Justice
- Keywords
- malignant pleural mesothelioma, asbestos exposure, asbestos carcinogenesis, chronic inflammation, autophagy, HMGB1, BAP1 mutation, IL-1β, TNF-α, anti-inflammatory therapy, early detection, therapeutic target, occupational exposure, mineral fibers, cancer susceptibility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.